

# Investigator Gazetteer Report - US States - Jan 2021

## US Clinical Trials By State

By Johan PE Karlberg, MD, PhD

<https://www.clinicaltrialmagnifier.org/>

### Objective and Material

The objective of this report is to display the current geographic distribution of industry-sponsored clinical trial sites in the United States.

The data represent industry-sponsored phase II/III clinical trials for a four year period, i.e. for trials registered with the US trial registry (clinicaltrials.gov) between January 1, 2017 to December 31, 2020.

### Results

The results are shown in Table 1 and Table 2.

#### *Site and Population Density*

Table 1 provides information on the number of sites per million population. Only US states with the highest density are included in this table – details about the remaining states are depicted in Table 2.

Florida with the second highest number of sites – after California – has also a relatively high number of sites in relation to the underlying population.

The population density ranges between 14 and 622 sites per million population with an average of 256.8.

Table 1. Population density: Number of industry-sponsored phase II/III trial sites by US states over a period of four full consecutive years (2017.01-2020.12).

State	Pop (Mil)	Sites (n)	Sites (%)	Sites / Mil
DISTRICT OF COLUMBIA	0.71	439	0.5	622
FLORIDA	21.48	10,903	11.7	508
UTAH	3.21	1,324	1.4	413
NEBRASKA	1.93	770	0.8	398
KANSAS	2.91	1,107	1.2	380
TENNESSEE	6.83	2,343	2.5	343
SOUTH CAROLINA	5.15	1,745	1.9	339
ARIZONA	7.28	2,410	2.6	331
OHIO	11.69	3,818	4.1	327
NORTH CAROLINA	10.49	3,401	3.7	324

#### *Study Sites by US States*

Table 2 gives the US states sorted after the number of sites.

During the study period of four years there were 93,0911 industry-sponsored phase II/III trial sites in the US.

California, Florida and Texas were the leading states together representing 33.4% of all sites.

The top ten states contributed with over half (58.4%) of the number of US sites.

## Investigator Gazetteer Report - US States - Jan 2021

Table 2. Number of industry-sponsored phase II/III trial sites by US states over a period of four full consecutive years (2017.01-2020.12).

<b>State</b>	<b>Pop (Mil)</b>	<b>Sites (n)</b>	<b>Sites (%)</b>	<b>Sites / Mil</b>
CALIFORNIA	39.51	11,476	12.3	290
FLORIDA	21.48	10,903	11.7	508
TEXAS	29.00	8,753	9.4	302
NEW YORK	19.45	4,815	5.2	248
OHIO	11.69	3,818	4.1	327
NORTH CAROLINA	10.49	3,401	3.7	324
PENNSYLVANIA	12.80	3,122	3.4	244
GEORGIA	10.62	2,868	3.1	270
ILLINOIS	12.67	2,694	2.9	213
ARIZONA	7.28	2,410	2.6	331
TENNESSEE	6.83	2,343	2.5	343
MICHIGAN	9.99	2,347	2.5	235
MASSACHUSETTS	6.95	2,160	2.3	311
VIRGINIA	8.54	2,004	2.2	235
MISSOURI	6.14	1,972	2.1	321
SOUTH CAROLINA	5.15	1,745	1.9	339
COLORADO	5.76	1,743	1.9	303
WASHINGTON	7.61	1,757	1.9	231
MARYLAND	6.05	1,691	1.8	280
NEW JERSEY	8.88	1,582	1.7	178
LOUISIANA	4.65	1,477	1.6	318
UTAH	3.21	1,324	1.4	413
ALABAMA	4.90	1,346	1.4	275
INDIANA	6.73	1,289	1.4	191
MINNESOTA	5.64	1,249	1.3	221
KANSAS	2.91	1,107	1.2	380
OREGON	4.22	1,080	1.2	256
CONNECTICUT	3.57	1,013	1.1	284
KENTUCKY	4.47	1,013	1.1	227
NEVADA	3.08	972	1.0	316
OKLAHOMA	3.96	973	1.0	246
WISCONSIN	5.82	851	0.9	146
NEBRASKA	1.93	770	0.8	398
ARKANSAS	3.02	726	0.8	241
IDAHO	1.79	545	0.6	305
IOWA	3.16	531	0.6	168
DISTRICT OF COLUMBIA	0.71	439	0.5	622
NEW MEXICO	2.10	373	0.4	178
MISSISSIPPI	2.98	352	0.4	118
SOUTH DAKOTA	0.88	279	0.3	315
RHODE ISLAND	1.06	325	0.3	307
MONTANA	1.07	259	0.3	242
DELAWARE	0.97	146	0.2	150
NEW HAMPSHIRE	1.36	201	0.2	148
HAWAII	1.42	181	0.2	128
MAINE	1.34	163	0.2	121
WEST VIRGINIA	1.79	197	0.2	110
VERMONT	0.62	121	0.1	194
NORTH DAKOTA	0.76	135	0.1	177
ALASKA	0.73	42	0.0	57
WYOMING	0.58	8	0.0	14